3 Under-$10 Canadian Stocks to Buy Right Now

These three unde-$10 Candian stocks offer high-growth prospects and deliver superior returns over the next three years.

| More on:
investment research

Image source: Getty Images

Investing in equity markets does not always require huge capital upfront. Even with a small but regular investment, one can create significant wealth over the long term. So if you are ready to invest, here are three Canadian stocks that you can buy under $10 to earn superior returns over the next three years.

B2Gold

B2Gold (TSX:BTO)(NYSEMKT:BTG) is a gold mining company with its mines located in Mali, Namibia, and the Philippines. The company had reported a solid first-quarter performance last week, with its adjusted EPS of $0.09, beating analysts’ expectations of $0.07. Meanwhile, its revenue of $362.3 million fell marginally short of analysts’ expectations.

Year over year, B2Gold’s revenue fell 4.7%. The decline in gold ounces sold during the quarter dragged the company’s top-line down. However, higher average realized gold prices offset some of the declines. Amid the planned waste stripping and lower mined ore grades, the company’s production declined during the quarter.

However, the company’s management expects its production to improve in the second half of this year, as the mining reaches the higher-grade zones. For this year, the company’s management expects its gold production to come in the range of 970,000 – 1,030,000 ounces. Over the last 30 days, gold prices have increased by 5.8%. Meanwhile, the uptrend could continue given the volatility in the broader equity markets, thereby benefiting gold-mining companies.

Aurora Cannabis

Amid the weakness in the cannabis sector, Aurora Cannabis (TSX:ACB)(NYSE:ACB) has lost close to 60% of its stock value from its February highs. The steep correction offers an excellent buying opportunity, given the expanding cannabis market amid increased legalization and the company’s growth initiatives.

Aurora Cannabis has captured a significant market share in the Canadian and international medical cannabis markets. Currently, it earns revenue from over 13 countries. The company focuses on increasing its market share and also expand its footprint into newer markets. Management also hopes that some of these medical channels would migrate to consumer channels in the coming years.

Its CBD brand, Reliva, has received a positive response from U.S. customers. The company is working on expanding the availability of the product across the United States. With its cash and cash equivalents standing at $565 million, Aurora Cannabis is well positioned to fund its growth initiatives.

WELL Health Technologies

Yesterday, WELL Health Technologies (TSX:WELL) had reported an impressive first-quarter performance, with its top-line increasing by 150% to $25.6 million. Its acquisitions over the last four quarters and organic growth in its various business units drove its revenue. It also posted positive adjusted EBITDA for the second quarter in a row, with its Canadian operations posting strong performance during the quarter.

Meanwhile, WELL Health acquired ExecHealth, IntraHealth and CRH Medical in the second quarter. With these acquisitions, the company’s annualized revenue run-rate is approaching $300 million per year. It also strengthened its billing and back-office segment by acquiring a 51% stake in Doctors Services Group. Further, the company has launched Health Records on iPhone, which would allow iPhone users to retrieve health records from participating clinics. So, the company’s growth prospects look healthy.

Meanwhile, amid the recent sell-off in tech stocks, WELL Health is trading at a 26.5% discount from its February highs. I believe investors should utilize the correction to accumulate the stock to earn superior returns.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

More on Tech Stocks

Man data analyze
Tech Stocks

3 Reasons Celestica Stock Is a Screaming Buy Now

These three reasons make Celestica stock a screaming buy for long-term investors.

Read more »

profit rises over time
Dividend Stocks

These 2 Dow Stocks Are Set to Soar in 2025 and Beyond

Two Dow Jones stocks are screaming buys but Canadians must hold them in an RRSP or RRIF to avoid paying…

Read more »

telehealth stocks
Tech Stocks

Well Health Stock: Buy, Sell, or Hold?

Another record-breaking quarter and strong demand sets the stage for continued momentum for Well Health stock.

Read more »

3 colorful arrows racing straight up on a black background.
Dividend Stocks

TSX Stocks Soaring Higher With No Signs of Slowing

Three TSX stocks continue to beat the market and could soar higher in an improving investment landscape.

Read more »

profit rises over time
Tech Stocks

2 Non-AI Tech Stocks to Buy in November for Better Returns

Not all AI stocks are riding the hype train, and for many investors, well-understood and predictable growth stocks might be…

Read more »

worry concern
Tech Stocks

In a Few Years, You’ll Probably Regret Not Owning BlackBerry Stock

Here’s why I believe BlackBerry could be one of the most overlooked Canadian tech stocks right now.

Read more »

A worker uses a double monitor computer screen in an office.
Tech Stocks

Is Constellation Software Stock a Buy for its 0.25% Dividend Yield?

Here's what investors may want to consider when it comes to Dollarama (TSX:DOL) and its relatively low dividend yield.

Read more »

Nurse talks with a teenager about medication
Tech Stocks

Shares of WELL Health Just Zoomed. Is It a Buy?

Given its improving financials and healthy growth prospects, WELL Health could deliver superior returns over the next three years.

Read more »